Hozumi M
Japan Immunoresearch Laboratories, Gunma, Japan.
Int J Hematol. 1998 Aug;68(2):107-29. doi: 10.1016/s0925-5710(98)00043-7.
Differentiation therapy in patients with acute promyelocytic leukemia (APL) using all-trans-retinoic acid (ATRA) has now been established as an effective strategy for the treatment of leukemia. However, the clinical response of patients with leukemias other than APL to differentiation inducers is limited, often with inconsistent outcome. Recently, numerous new differentiation inducers for various leukemia cells have been developed, some of which have had therapeutic effects on various leukemias in preclinical and clinical trials. Additionally, molecular control mechanisms of differentiation, and apoptosis of various leukemia cells by differentiation inducers have been studied extensively. These studies suggest that problems underlying the current discrepancy between preclinical and clinical therapeutic efficacy of leukemias can be overcome by these basic studies together with multidisciplinary studies on the therapy of leukemias in combination with differentiation therapy and other conventional therapies.
使用全反式维甲酸（ATRA）对急性早幼粒细胞白血病（APL）患者进行分化治疗现已成为治疗白血病的一种有效策略。然而，除APL外的其他白血病患者对分化诱导剂的临床反应有限，且结果往往不一致。最近，已开发出多种针对各种白血病细胞的新型分化诱导剂，其中一些在临床前和临床试验中对各种白血病具有治疗作用。此外，还广泛研究了分化的分子控制机制以及分化诱导剂对各种白血病细胞凋亡的影响。这些研究表明，通过这些基础研究以及白血病治疗与分化治疗和其他传统疗法相结合的多学科研究，可以克服目前白血病临床前和临床治疗效果差异背后的问题。
